11 © Debiopharm Group 2009

Debiopharm and innovation

2 © Debiopharm Group 200928.05.2009

. LausanneMartigny

Paris..Montreal

Debiopharm Group

Founded in 1979, privately owned, financially independant 300 Employees worldwide with headquarters in Lausanne,

Switzerland 42 % scientists (MDs, PhDs, pharmacists)

> 400 international network of experts ‘on call’ Key expertise : Drug Development

3 © Debiopharm Group 200928.05.2009

Business Model: Bridging Discovery to Market

Fully funded drug development

& innovation

Discovery

Pharmasanofi-aventis, Ipsen, Watson, Pfizer and others

DEBIOPHARM GROUP

from molecule to drug approval

Market

Academic institutionsBiotechStart upPharmaKirin, EPFL, Tulane University, Shanghai Institute (SIMM),Nanocarrier and others

Added Value

4 © Debiopharm Group 200928.05.2009

.

Eloxatin ® awarded 2004 Prix Galien

- Indications: 1st line, 2nd line, adjuvant, neoadjuvant metastatic colorectal cancer

- sanofi-aventis’ # 6 product- Current licensee sales : 2.3 billion USD

Decapeptyl ® and Trelstar ® (USA)Indications: advanced prostate cancer,

endometriosis, precocious puberty, uterine fibroids, Paraphilia

- Ipsen’s # 1 product- Current licensee sales: 400 million USD

Our products

5 © Debiopharm Group 200928.05.2009

Poly-Lactide-Glycolide : PLG

HydrolysisLactic acid + Glycolic acid

Degradation time (1 week to 6 months) function of :

• Ratio L:G

• Mw (Inherant viscosity, i.v.)

• Terminal end groups (laurylester, PEG, -COOH)

6 © Debiopharm Group 200928.05.2009

Pt loaded Polymeric Nano-Micelles

MeO (CH2CH2O)n NH CO

CHHN

CH2

CH2

CO ONa

H

m

CH2CH2CH2

H2N

PtOOCN

H2

OOC COOPt

NH2H2N

OOC

+

H2N

NH2

Pt

ONO2

ONO2

Mean diameter

30 nm

7 © Debiopharm Group 200928.05.2009

Pt loaded Polymeric Nano-Micelles

Total Platinum in plasma in C38 mouse model after IV injection of ND formulations or L-OHP

10

100

1000

10000

100000

0 24 48 72 96

hours

ng

Pt/

ml

L-OHP (060016)

L-OHP (060048)

ND-01-01 (060048)

ND-01-02 (060016)

ND-01-03 (060016)

AUC 0-96h total platinum in tumor

020000400006000080000

100000120000140000160000180000200000

l-OHP ND-01-01

ng P

t/g.h

8 © Debiopharm Group 200928.05.2009

In vivo bioluminescent imaging (IVIS Imaging System, Xenogen) HeLa-Luc i.p metastases at day 15 (D-luciferin injected at 150 mg/kg 10 minutes before)

B. Saline; C. oxaliplatin 6 mg/kg; D. DACHPt micelles 6 mg/kg.

Antitumor Activity assay

9 © Debiopharm Group 200928.05.2009

O

Re-design of Drugs

EXAMPLE: synthesis of Debio-025 (Anti-HcV)

Immunosuppressive Antiviral

10 © Debiopharm Group 200928.05.2009

Conclusion: Origine de l’innovation

Bottom up (production) Curiosité, analyse (comprendre pour innover, améliorer)

Top down (R&D) Association d’idées différentes Expression du besoin Idées de ruptures/passer les barrières Confronter des visions différentes

11 © Debiopharm Group 200928.05.2009

Conditions cadres pour innovation CH

EPFL learning center

12 © Debiopharm Group 200928.05.2009

Conditions cadres valaisannes, il faut rêver!